Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
This study is ongoing, but not recruiting participants.
Sponsor:
Applied Genetic Technologies Corp
Collaborators:
Oregon Health and Science University
University of Massachusetts, Worcester
Information provided by (Responsible Party):
Applied Genetic Technologies Corp
ClinicalTrials.gov Identifier:
NCT00749957
First received: September 8, 2008
Last updated: March 6, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | December 2027 |
| Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |